| Literature DB >> 33118310 |
Emma Russell1, Ana Agua-Doce1, Lotte Carr1, Asha Malla1, Kerol Bartolovic1, Dina Levi1, Carl Henderson1, Debipriya Das1, Hefin Rhys1, Philip Hobson1, Sukhveer Purewal1, Andrew Riddell1.
Abstract
In March 2020, with lockdown due to the coronavirus pandemic underway, the Francis Crick Institute (the Crick) regeared its research laboratories into clinical testing facilities. Two pipelines were established, one for polymerase chain reaction and the other for Serology. This article discusses the Cricks Flow Cytometry Science Technology Platform (Flow STP) role in setting up the Serology pipeline. Pipeline here referring to the overarching processes in place to facilitate the receipt of human sera through to a SARs-CoV-2 enzyme-linked immunosorbent assay result. We examine the challenges that had to be overcome by a research laboratory to incorporate clinical diagnostics and the processes by which this was achieved. It describes the governance required to run the service, the design of the standard operating procedures (SOPs) and pipeline, the setting up of the assay, the validation required to show the robustness of the pipeline and reporting the results of the assay. Finally, as the lockdown started to ease in June 2020, it examines how this new service affects the daily running of the Flow STP.Entities:
Keywords: Assay; Covid-19; Cytometry; Development; ELISA; Flow; Pipeline; SARs-CoV-2; SRL; Validation; clinical; pandemic; testing
Mesh:
Year: 2020 PMID: 33118310 PMCID: PMC7894326 DOI: 10.1002/cyto.a.24248
Source DB: PubMed Journal: Cytometry A ISSN: 1552-4922 Impact factor: 4.714